LitCovid-sample-Enju  

PMC:7228307 / 2471-62115 JSONTXT 27 Projects

Annnotations TAB TSV DIC JSON TextAE-old TextAE

Id Subject Object Predicate Lexical cue
T0 54880-54883 DT denotes The
T1 54884-54894 NN denotes expression
T2 54895-54897 IN denotes of
T3 54898-54905 NN denotes FcγRIIb
T4 54906-54908 IN denotes on
T5 54909-54913 NNP denotes LSEC
T6 54914-54917 CC denotes and
T7 54918-54921 PRP-DOLLAR- denotes its
T8 54922-54928 NN denotes action
T9 54929-54931 IN denotes in
T10 54932-54935 DT denotes the
T11 54936-54946 NN denotes “sweeping”
T12 54947-54949 CC denotes or
T13 54950-54957 NN denotes removal
T14 54958-54960 IN denotes of
T15 54961-54966 JJ denotes small
T16 54967-54973 JJ denotes immune
T17 54974-54983 NNS denotes complexes
T18 54984-54987 VBZ denotes has
T19 54988-54994 VBN denotes opened
T20 54995-54997 RP denotes up
T21 54998-55001 JJ denotes new
T22 55002-55015 NNS denotes possibilities
T23 55016-55019 IN denotes for
T24 55020-55023 DT denotes the
T25 55024-55035 NN denotes application
T26 55036-55038 IN denotes of
T27 55039-55056 VBG denotes FcγRIIb‐enhancing
T28 55057-55073 NN denotes modifications.17
T29 55074-55084 NNS denotes Antibodies
T30 55085-55087 CC denotes or
T31 55088-55090 NN denotes Fc
T32 55091-55097 NN denotes fusion
T33 55098-55106 NNS denotes proteins
T34 55106-55107 -COMMA- denotes ,
T35 55108-55113 WP-DOLLAR- denotes whose
T36 55114-55121 JJ denotes primary
T37 55122-55125 NN denotes MOA
T38 55126-55128 VBZ denotes is
T39 55129-55132 DT denotes the
T40 55133-55147 NN denotes neutralization
T41 55148-55150 IN denotes of
T42 55151-55158 JJ denotes soluble
T43 55159-55168 NNS denotes molecules
T44 55169-55173 JJ denotes such
T45 55174-55176 IN denotes as
T46 55177-55180 NN denotes IgE
T47 55181-55183 CC denotes or
T48 55184-55193 NNS denotes cytokines
T49 55193-55194 -COMMA- denotes ,
T50 55195-55198 VBP denotes are
T51 55199-55211 RB denotes particularly
T52 55212-55222 JJ denotes attractive
T53 55223-55233 NNS denotes candidates
T54 55234-55237 IN denotes for
T55 55238-55242 DT denotes this
T56 55243-55251 NN denotes approach
T57 55253-55269 NN denotes Proof‐of‐concept
T58 55270-55273 IN denotes for
T59 55274-55278 DT denotes this
T60 55279-55287 NN denotes strategy
T61 55288-55291 VBZ denotes has
T62 55292-55296 VBN denotes been
T63 55297-55309 VBN denotes demonstrated
T64 55310-55312 IN denotes in
T65 55313-55325 JJ denotes experimental
T66 55326-55335 NN denotes models.48
T67 55336-55342 RB denotes Indeed
T68 55342-55343 -COMMA- denotes ,
T69 55344-55348 DT denotes this
T70 55349-55352 MD denotes may
T71 55353-55355 VB denotes be
T72 55356-55357 DT denotes a
T73 55358-55369 JJ denotes significant
T74 55370-55379 NN denotes component
T75 55380-55382 IN denotes of
T76 55383-55386 DT denotes the
T77 55387-55392 JJ denotes rapid
T78 55393-55406 NN denotes disappearance
T79 55407-55409 IN denotes of
T80 55410-55413 NN denotes IgE
T81 55414-55418 IN denotes from
T82 55419-55422 DT denotes the
T83 55423-55434 NN denotes circulation
T84 55435-55437 IN denotes of
T85 55438-55446 NNS denotes patients
T86 55447-55454 VBN denotes treated
T87 55455-55459 IN denotes with
T88 55460-55463 DT denotes the
T89 55464-55472 NN denotes anti‐IgE
T90 55473-55481 NN denotes XmAb7195
T91 55482-55492 VBG denotes containing
T92 55493-55496 DT denotes the
T93 55497-55504 NN denotes FcγRIIb
T94 55505-55514 VBG denotes enhancing
T95 55515-55521 NNP denotes “SELF”
T96 55522-55535 NNS denotes modifications
T97 55535-55536 -COMMA- denotes ,
T98 55537-55539 IN denotes as
T99 55540-55549 VBN denotes described
T100 55550-55560 RB denotes previously
T101 55563-55569 JJ denotes Immune
T102 55570-55577 NN denotes agonism
T103 55578-55585 IN denotes through
T104 55586-55590 NN denotes FcγR
T105 55591-55602 NN denotes scaffolding
T106 55603-55612 JJ denotes Agonistic
T107 55613-55617 NNS denotes mAbs
T108 55618-55624 VBP denotes induce
T109 55625-55634 NNS denotes responses
T110 55635-55637 IN denotes in
T111 55638-55644 NN denotes target
T112 55645-55650 NNS denotes cells
T113 55651-55653 IN denotes by
T114 55654-55665 VBG denotes stimulating
T115 55666-55675 NN denotes signaling
T116 55676-55678 IN denotes of
T117 55679-55684 PRP-DOLLAR- denotes their
T118 55685-55694 JJ denotes molecular
T119 55695-55701 NN denotes target
T120 55703-55712 RB denotes Typically
T121 55712-55713 -COMMA- denotes ,
T122 55714-55718 DT denotes this
T123 55719-55721 VBZ denotes is
T124 55722-55724 TO denotes to
T125 55725-55731 CC denotes either
T126 55732-55739 VB denotes enhance
T127 55740-55749 NN denotes antitumor
T128 55750-55758 NN denotes immunity
T129 55759-55761 IN denotes by
T130 55762-55770 VBG denotes engaging
T131 55771-55784 JJ denotes costimulatory
T132 55785-55794 NNS denotes molecules
T133 55795-55797 IN denotes on
T134 55798-55816 JJ denotes antigen‐presenting
T135 55817-55822 NNS denotes cells
T136 55823-55825 CC denotes or
T137 55826-55827 NN denotes T
T138 55828-55833 NNS denotes cells
T139 55834-55835 -LRB- denotes (
T140 55835-55839 FW denotes i.e.
T141 55840-55844 NN denotes CD40
T142 55844-55845 -COMMA- denotes ,
T143 55846-55851 NN denotes 4‐1BB
T144 55851-55852 -COMMA- denotes ,
T145 55853-55857 NN denotes OX40
T146 55857-55858 -RRB- denotes )
T147 55859-55861 CC denotes or
T148 55862-55869 VB denotes promote
T149 55870-55879 NN denotes apoptosis
T150 55880-55882 IN denotes by
T151 55883-55891 VBG denotes engaging
T152 55892-55897 NN denotes death
T153 55898-55907 NNS denotes receptors
T154 55908-55910 IN denotes on
T155 55911-55917 NN denotes cancer
T156 55918-55923 NNS denotes cells
T157 55924-55925 -LRB- denotes (
T158 55925-55929 FW denotes i.e.
T159 55930-55933 NN denotes DR4
T160 55933-55934 -COMMA- denotes ,
T161 55935-55938 NN denotes DR5
T162 55938-55939 -COMMA- denotes ,
T163 55940-55943 NN denotes Fas
T164 55943-55944 -RRB- denotes )
T165 55949-55952 DT denotes The
T166 55953-55957 NN denotes role
T167 55958-55960 IN denotes of
T168 55961-55965 NN denotes FcγR
T169 55966-55968 IN denotes in
T170 55969-55972 DT denotes the
T171 55973-55979 NN denotes action
T172 55980-55982 IN denotes of
T173 55983-55988 DT denotes these
T174 55989-55994 NNS denotes types
T175 55995-55997 IN denotes of
T176 55998-56002 NNS denotes mAbs
T177 56003-56010 VBZ denotes appears
T178 56011-56013 TO denotes to
T179 56014-56016 VB denotes be
T180 56017-56026 RB denotes primarily
T181 56027-56029 IN denotes as
T182 56030-56031 DT denotes a
T183 56032-56040 NN denotes scaffold
T184 56042-56049 NN denotes FcγRIIb
T185 56050-56052 VBZ denotes is
T186 56053-56058 RB denotes often
T187 56059-56062 DT denotes the
T188 56063-56074 JJ denotes predominate
T189 56075-56083 NN denotes receptor
T190 56084-56092 VBN denotes involved
T191 56093-56096 CC denotes and
T192 56097-56100 DT denotes the
T193 56101-56107 NN denotes extent
T194 56108-56110 IN denotes of
T195 56111-56114 PRP-DOLLAR- denotes its
T196 56115-56126 NN denotes involvement
T197 56127-56129 VBZ denotes is
T198 56130-56137 JJ denotes complex
T199 56139-56141 IN denotes In
T200 56142-56145 DT denotes the
T201 56146-56150 NN denotes case
T202 56151-56153 IN denotes of
T203 56154-56158 NN denotes CD40
T204 56158-56159 -COMMA- denotes ,
T205 56160-56163 DT denotes the
T206 56164-56170 NN denotes degree
T207 56171-56173 IN denotes of
T208 56174-56181 NN denotes FcγRIIb
T209 56182-56193 NN denotes scaffolding
T210 56194-56201 NN denotes potency
T211 56202-56204 VBZ denotes is
T212 56205-56211 VBN denotes linked
T213 56212-56214 TO denotes to
T214 56215-56218 DT denotes the
T215 56219-56226 NN denotes epitope
T216 56227-56235 NN denotes location
T217 56236-56238 IN denotes of
T218 56239-56242 DT denotes the
T219 56243-56252 VBG denotes targeting
T220 56253-56256 NN denotes mAb
T221 56257-56261 IN denotes with
T222 56262-56269 JJR denotes greater
T223 56270-56277 NN denotes potency
T224 56278-56282 VBN denotes seen
T225 56283-56286 IN denotes for
T226 56287-56295 NN denotes membrane
T227 56296-56304 JJ denotes proximal
T228 56305-56316 NN denotes epitopes.43
T229 56316-56317 -COMMA- denotes ,
T230 56318-56321 CD denotes 117
T231 56322-56324 PRP denotes It
T232 56325-56327 VBZ denotes is
T233 56328-56332 RB denotes also
T234 56333-56343 JJ denotes noteworthy
T235 56344-56348 IN denotes that
T236 56349-56358 VBG denotes depending
T237 56359-56361 IN denotes on
T238 56362-56365 DT denotes the
T239 56366-56373 NN denotes epitope
T240 56374-56382 NN denotes location
T241 56382-56383 -COMMA- denotes ,
T242 56384-56387 DT denotes the
T243 56388-56399 NN denotes scaffolding
T244 56400-56402 IN denotes of
T245 56403-56412 NN denotes anti‐CD40
T246 56413-56417 NNS denotes mAbs
T247 56418-56421 MD denotes may
T248 56422-56429 VB denotes convert
T249 56430-56440 NN denotes antagonist
T250 56441-56445 NNS denotes mAbs
T251 56446-56448 TO denotes to
T252 56449-56458 JJ denotes agonistic
T253 56460-56471 NN denotes Engineering
T254 56472-56474 IN denotes of
T255 56475-56478 DT denotes the
T256 56479-56483 NN denotes IgG1
T257 56484-56486 NN denotes Fc
T258 56487-56493 NN denotes region
T259 56494-56497 IN denotes for
T260 56498-56506 VBN denotes enhanced
T261 56507-56513 CC denotes and/or
T262 56514-56522 JJ denotes specific
T263 56523-56530 NN denotes binding
T264 56531-56533 TO denotes to
T265 56534-56541 NN denotes FcγRIIb
T266 56542-56545 MD denotes can
T267 56546-56553 RB denotes greatly
T268 56554-56561 VB denotes improve
T269 56562-56571 JJ denotes agonistic
T270 56572-56583 NN denotes function.72
T271 56583-56584 -COMMA- denotes ,
T272 56585-56588 CD denotes 118
T273 56588-56589 -COMMA- denotes ,
T274 56590-56593 CD denotes 119
T275 56593-56594 -COMMA- denotes ,
T276 56595-56598 CD denotes 120
T277 56599-56603 JJ denotes Such
T278 56604-56613 NNS denotes mutations
T279 56614-56621 VBD denotes induced
T280 56622-56635 RB denotes significantly
T281 56636-56643 JJR denotes greater
T282 56644-56653 JJ denotes agonistic
T283 56654-56662 NN denotes activity
T284 56663-56665 IN denotes in
T285 56666-56668 DT denotes an
T286 56669-56677 NN denotes anti‐DR5
T287 56678-56683 NN denotes model
T288 56684-56691 IN denotes through
T289 56692-56701 VBN denotes increased
T290 56702-56711 NN denotes induction
T291 56712-56714 IN denotes of
T292 56715-56724 JJ denotes apoptotic
T293 56725-56730 NN denotes death
T294 56731-56734 CC denotes and
T295 56735-56744 VBD denotes decreased
T296 56745-56750 NN denotes tumor
T297 56751-56757 NN denotes growth
T298 56758-56766 VBN denotes compared
T299 56767-56771 IN denotes with
T300 56772-56782 JJ denotes unmodified
T301 56783-56791 NN denotes IgG1.121
T302 56792-56795 DT denotes The
T303 56796-56802 NNP denotes “SELF”
T304 56803-56816 NNS denotes modifications
T305 56817-56821 WDT denotes that
T306 56822-56834 RB denotes dramatically
T307 56835-56838 CC denotes and
T308 56839-56850 RB denotes selectively
T309 56851-56859 VBP denotes increase
T310 56860-56868 NN denotes affinity
T311 56869-56872 IN denotes for
T312 56873-56880 NN denotes FcγRIIb
T313 56881-56885 VBP denotes have
T314 56886-56890 RB denotes also
T315 56891-56895 VBN denotes been
T316 56896-56900 VBN denotes used
T317 56901-56903 TO denotes to
T318 56904-56911 VB denotes enhance
T319 56912-56918 JJ denotes immune
T320 56919-56926 NN denotes agonism
T321 56927-56929 IN denotes in
T322 56930-56932 DT denotes an
T323 56933-56942 NN denotes anti‐OX40
T324 56943-56952 NN denotes model.122
T325 56953-56956 DT denotes The
T326 56957-56973 NN denotes incorporation of
T327 56974-56977 DT denotes the
T328 56978-56979 -DQS- denotes "
T329 56979-56982 NN denotes V12
T330 56982-56983 '' denotes "
T331 56984-56986 NN denotes Fc
T332 56987-56996 NNS denotes mutations
T333 56997-57001 IN denotes into
T334 57002-57006 NN denotes IgG1
T335 57007-57019 RB denotes specifically
T336 57020-57027 VBP denotes enhance
T337 57028-57035 NN denotes FcγRIIb
T338 57036-57047 NN denotes interaction
T339 57048-57056 RB denotes 200‐fold
T340 57056-57057 -COMMA- denotes ,
T341 57058-57068 VBG denotes conferring
T342 57069-57072 DT denotes the
T343 57073-57081 VBN denotes enhanced
T344 57082-57091 JJ denotes agonistic
T345 57092-57100 NN denotes activity
T346 57101-57103 IN denotes of
T347 57104-57106 DT denotes an
T348 57107-57117 NN denotes anti‐CD137
T349 57118-57126 NN denotes antibody
T350 57127-57130 CC denotes and
T351 57131-57133 DT denotes an
T352 57134-57143 NN denotes anti‐OX40
T353 57144-57151 NN denotes mAb.115
T354 57151-57152 -COMMA- denotes ,
T355 57153-57156 CD denotes 122
T356 57158-57164 NNP denotes Future
T357 57165-57176 NNP denotes Engineering
T358 57177-57187 NNPS denotes Strategies
T359 57188-57198 JJ denotes Monoclonal
T360 57199-57209 NNS denotes antibodies
T361 57210-57213 VBP denotes are
T362 57214-57220 JJ denotes potent
T363 57221-57233 NNS denotes therapeutics
T364 57234-57236 IN denotes in
T365 57237-57238 DT denotes a
T366 57239-57245 NN denotes number
T367 57246-57248 IN denotes of
T368 57249-57256 JJ denotes chronic
T369 57257-57259 CC denotes or
T370 57260-57264 RB denotes once
T371 57265-57274 JJ denotes incurable
T372 57275-57283 NNS denotes diseases
T373 57285-57292 RB denotes However
T374 57292-57293 -COMMA- denotes ,
T375 57294-57299 EX denotes there
T376 57300-57302 VBZ denotes is
T377 57303-57308 RB denotes still
T378 57309-57318 JJ denotes extensive
T379 57319-57324 JJ denotes unmet
T380 57325-57333 JJ denotes clinical
T381 57334-57338 NN denotes need
T382 57339-57341 RB denotes as
T383 57342-57346 RB denotes well
T384 57347-57349 IN denotes as
T385 57350-57362 JJ denotes considerable
T386 57363-57367 NN denotes room
T387 57368-57371 IN denotes for
T388 57372-57383 NN denotes improvement
T389 57384-57386 IN denotes in
T390 57387-57391 JJ denotes many
T391 57392-57400 VBG denotes existing
T392 57401-57413 NNS denotes therapeutics
T393 57415-57422 JJ denotes Further
T394 57423-57436 NN denotes understanding
T395 57437-57439 IN denotes of
T396 57440-57443 WRB denotes how
T397 57444-57452 NN denotes antibody
T398 57453-57462 NN denotes structure
T399 57463-57470 VBZ denotes affects
T400 57471-57475 NN denotes FcγR
T401 57476-57484 NN denotes function
T402 57485-57487 VBZ denotes is
T403 57488-57497 JJ denotes essential
T404 57498-57501 IN denotes for
T405 57502-57508 JJ denotes future
T406 57509-57520 NN denotes development
T407 57521-57523 IN denotes of
T408 57524-57528 RBR denotes more
T409 57529-57535 JJ denotes potent
T410 57536-57539 CC denotes and
T411 57540-57549 JJ denotes effective
T412 57550-57554 NNS denotes mAbs
T413 57556-57563 RB denotes Already
T414 57563-57564 -COMMA- denotes ,
T415 57565-57576 NN denotes engineering
T416 57577-57579 IN denotes of
T417 57580-57583 DT denotes the
T418 57584-57587 NN denotes IgG
T419 57588-57590 NN denotes Fc
T420 57591-57594 CC denotes and
T421 57595-57598 PRP-DOLLAR- denotes its
T422 57599-57605 NN denotes glycan
T423 57606-57609 VBZ denotes has
T424 57610-57616 VBN denotes proved
T425 57617-57618 DT denotes a
T426 57619-57625 JJ denotes potent
T427 57626-57629 CC denotes and
T428 57630-57639 JJ denotes effective
T429 57640-57648 NN denotes approach
T430 57649-57652 IN denotes for
T431 57653-57663 VBG denotes increasing
T432 57664-57667 DT denotes the
T433 57668-57676 JJ denotes clinical
T434 57677-57690 NN denotes effectiveness
T435 57690-57691 -COMMA- denotes ,
T436 57692-57702 JJ denotes functional
T437 57703-57714 NN denotes specificity
T438 57715-57718 CC denotes and
T439 57719-57725 NN denotes safety
T440 57726-57728 IN denotes of
T441 57729-57740 JJ denotes therapeutic
T442 57741-57745 NNS denotes mAbs
T443 57746-57749 CC denotes and
T444 57750-57752 VBZ denotes is
T445 57753-57755 DT denotes an
T446 57756-57764 VBG denotes emerging
T447 57765-57772 NN denotes pathway
T448 57773-57775 TO denotes to
T449 57776-57779 DT denotes the
T450 57780-57791 NN denotes development
T451 57792-57794 IN denotes of
T452 57795-57798 DT denotes the
T453 57799-57809 NN denotes “next‐gen”
T454 57810-57822 NNS denotes therapeutics
T455 57824-57830 JJ denotes Future
T456 57831-57841 NNS denotes directions
T457 57842-57844 IN denotes in
T458 57845-57848 DT denotes the
T459 57849-57860 NN denotes development
T460 57861-57864 CC denotes and
T461 57865-57868 NN denotes use
T462 57869-57871 IN denotes of
T463 57872-57883 JJ denotes therapeutic
T464 57884-57894 NNS denotes antibodies
T465 57895-57901 MD denotes should
T466 57902-57914 RB denotes increasingly
T467 57915-57920 VB denotes mimic
T468 57921-57927 JJ denotes normal
T469 57928-57938 JJ denotes protective
T470 57939-57947 NN denotes antibody
T471 57948-57957 NNS denotes responses
T472 57957-57958 -COMMA- denotes ,
T473 57959-57964 WDT denotes which
T474 57965-57968 VBP denotes are
T475 57969-57979 JJ denotes polyclonal
T476 57980-57983 CC denotes and
T477 57984-57992 VBN denotes elicited
T478 57993-57995 IN denotes in
T479 57996-57999 DT denotes the
T480 58000-58007 NN denotes context
T481 58008-58010 IN denotes of
T482 58011-58017 JJ denotes innate
T483 58018-58026 NN denotes receptor
T484 58027-58037 NN denotes engagement
T485 58038-58043 WDT denotes which
T486 58044-58052 VBZ denotes includes
T487 58053-58056 DT denotes the
T488 58057-58060 NNS denotes FcR
T489 58061-58063 RB denotes as
T490 58064-58068 RB denotes well
T491 58069-58071 IN denotes as
T492 58072-58077 JJ denotes other
T493 58078-58088 RB denotes powerfully
T494 58089-58099 JJ denotes responsive
T495 58100-58107 NNS denotes systems
T496 58108-58117 VBG denotes including
T497 58118-58121 DT denotes the
T498 58122-58131 JJ denotes Toll‐like
T499 58132-58141 NNS denotes receptors
T500 58142-58145 CC denotes and
T501 58146-58156 NN denotes complement
T502 58157-58166 NNS denotes receptors
T503 58168-58179 RB denotes Furthermore
T504 58179-58180 -COMMA- denotes ,
T505 58181-58184 DT denotes the
T506 58185-58190 JJ denotes mixed
T507 58191-58199 NN denotes subclass
T508 58200-58206 NN denotes nature
T509 58207-58209 IN denotes of
T510 58210-58215 DT denotes these
T511 58216-58222 JJ denotes normal
T512 58223-58231 NN denotes antibody
T513 58232-58241 NNS denotes responses
T514 58242-58250 VBZ denotes suggests
T515 58251-58255 IN denotes that
T516 58256-58269 NNS denotes circumstances
T517 58270-58273 MD denotes may
T518 58274-58279 VB denotes arise
T519 58280-58282 IN denotes in
T520 58283-58294 JJ denotes therapeutic
T521 58295-58305 NNS denotes strategies
T522 58306-58311 WRB denotes where
T523 58312-58317 EX denotes there
T524 58318-58320 VBZ denotes is
T525 58321-58326 NN denotes value
T526 58327-58329 IN denotes in
T527 58330-58336 VBG denotes having
T528 58337-58347 RB denotes distinctly
T529 58348-58356 VBN denotes modified
T530 58357-58360 NNS denotes Fcs
T531 58361-58364 IN denotes for
T532 58365-58368 DT denotes the
T533 58369-58376 JJ denotes nuanced
T534 58377-58387 NN denotes engagement
T535 58388-58390 IN denotes of
T536 58391-58400 JJ denotes different
T537 58401-58405 NN denotes FcγR
T538 58406-58412 NN denotes family
T539 58413-58420 NNS denotes members
T540 58422-58432 NNS denotes Treatments
T541 58433-58443 VBG denotes comprising
T542 58444-58452 JJ denotes multiple
T543 58453-58457 NNS denotes mAbs
T544 58458-58461 CC denotes and
T545 58462-58468 JJ denotes immune
T546 58469-58479 NNS denotes stimulants
T547 58480-58483 VBP denotes are
T548 58484-58489 IN denotes under
T549 58490-58503 NN denotes investigation
T550 58504-58506 IN denotes in
T551 58507-58517 JJ denotes infectious
T552 58518-58525 NN denotes disease
T553 58526-58529 IN denotes for
T554 58530-58544 NN denotes neutralization
T555 58545-58553 NN denotes coverage
T556 58554-58556 IN denotes of
T557 58557-58564 JJ denotes variant
T558 58565-58572 NNS denotes strains
T559 58574-58580 RB denotes Indeed
T560 58580-58581 -COMMA- denotes ,
T561 58582-58586 PDT denotes such
T562 58587-58589 DT denotes an
T563 58590-58598 NN denotes approach
T564 58599-58602 MD denotes may
T565 58603-58605 VB denotes be
T566 58606-58610 RBS denotes most
T567 58611-58620 JJ denotes effective
T568 58621-58623 IN denotes in
T569 58624-58632 VBG denotes emerging
T570 58633-58643 JJ denotes infectious
T571 58644-58651 NN denotes disease
T572 58652-58656 JJ denotes such
T573 58657-58659 IN denotes as
T574 58660-58666 JJ denotes severe
T575 58667-58672 JJ denotes acute
T576 58673-58684 JJ denotes respiratory
T577 58685-58693 NN denotes syndrome
T578 58694-58705 NN denotes coronavirus
T579 58706-58707 CD denotes 2
T580 58708-58709 -LRB- denotes (
T581 58709-58719 NN denotes SARS‐CoV‐2
T582 58719-58720 -RRB- denotes )
T583 58721-58730 NN denotes infection
T584 58732-58735 DT denotes The
T585 58736-58739 NN denotes use
T586 58740-58742 IN denotes of
T587 58743-58751 JJ denotes multiple
T588 58752-58756 NNS denotes mAbs
T589 58757-58765 VBN denotes tailored
T590 58766-58769 IN denotes for
T591 58770-58778 JJ denotes distinct
T592 58779-58787 NN denotes effector
T593 58788-58797 NNS denotes functions
T594 58798-58801 CC denotes and
T595 58802-58811 VBG denotes targeting
T596 58812-58821 JJ denotes different
T597 58822-58830 NNS denotes epitopes
T598 58831-58835 MD denotes will
T599 58836-58844 VB denotes maximize
T600 58845-58848 DT denotes the
T601 58849-58860 NN denotes opportunity
T602 58861-58864 IN denotes for
T603 58865-58876 NN denotes cocktailing
T604 58877-58879 IN denotes of
T605 58880-58888 NN denotes effector
T606 58889-58898 NNS denotes functions
T607 58899-58901 IN denotes in
T608 58902-58911 JJ denotes different
T609 58912-58917 NNS denotes types
T610 58918-58920 IN denotes of
T611 58921-58929 NNS denotes diseases
T612 58931-58937 RB denotes Indeed
T613 58937-58938 -COMMA- denotes ,
T614 58939-58941 IN denotes in
T615 58942-58943 DT denotes a
T616 58944-58949 JJ denotes small
T617 58950-58953 CC denotes but
T618 58954-58966 JJ denotes contemporary
T619 58967-58974 NN denotes example
T620 58975-58982 IN denotes outside
T621 58983-58985 IN denotes of
T622 58986-58996 JJ denotes infectious
T623 58997-59004 NN denotes disease
T624 59004-59005 -COMMA- denotes ,
T625 59006-59009 DT denotes the
T626 59010-59022 NNP denotes FDA‐approved
T627 59023-59034 NN denotes combination
T628 59035-59037 IN denotes in
T629 59038-59052 NN denotes adenocarcinoma
T630 59053-59060 NN denotes therapy
T631 59061-59065 VBZ denotes uses
T632 59066-59067 DT denotes a
T633 59068-59076 NN denotes cocktail
T634 59077-59079 IN denotes of
T635 59080-59083 CD denotes two
T636 59084-59088 NNS denotes mAbs
T637 59088-59089 -COMMA- denotes ,
T638 59090-59100 NN denotes pertuzumab
T639 59101-59104 CC denotes and
T640 59105-59116 NN denotes trastuzumab
T641 59116-59117 -COMMA- denotes ,
T642 59118-59125 IN denotes against
T643 59126-59134 NN denotes Her2.123
T644 59135-59141 RB denotes Rather
T645 59142-59146 IN denotes than
T646 59147-59150 CD denotes one
T647 59151-59155 NN denotes type
T648 59156-59158 IN denotes of
T649 59159-59161 NN denotes Fc
T650 59162-59164 TO denotes to
T651 59165-59172 VB denotes conquer
T652 59173-59176 DT denotes all
T653 59176-59177 -COMMA- denotes ,
T654 59178-59181 DT denotes the
T655 59182-59190 JJ denotes combined
T656 59191-59194 NN denotes use
T657 59195-59197 IN denotes of
T658 59198-59211 RB denotes appropriately
T659 59212-59220 VBN denotes selected
T660 59221-59225 NNS denotes mAbs
T661 59226-59231 WP-DOLLAR- denotes whose
T662 59232-59242 JJ denotes individual
T663 59243-59253 NNS denotes components
T664 59254-59257 VBP denotes are
T665 59258-59266 VBN denotes enhanced
T666 59267-59270 IN denotes for
T667 59271-59274 DT denotes the
T668 59275-59285 NN denotes engagement
T669 59286-59288 IN denotes of
T670 59289-59298 JJ denotes different
T671 59299-59303 NN denotes FcγR
T672 59304-59311 NNS denotes members
T673 59312-59315 MD denotes may
T674 59316-59323 VB denotes utilize
T675 59324-59332 JJ denotes multiple
T676 59333-59343 NNS denotes components
T677 59344-59346 IN denotes of
T678 59347-59350 DT denotes the
T679 59351-59359 NN denotes spectrum
T680 59360-59362 IN denotes of
T681 59363-59371 NN denotes effector
T682 59372-59381 NNS denotes responses
T683 59382-59384 IN denotes on
T684 59385-59390 NN denotes offer
T685 59391-59393 IN denotes by
T686 59394-59397 DT denotes the
T687 59398-59404 JJ denotes immune
T688 59405-59411 NN denotes system
T689 59413-59417 JJ denotes Such
T690 59418-59428 NN denotes “next‐gen”
T691 59429-59438 NNS denotes biologics
T692 59439-59443 MD denotes will
T693 59444-59449 VB denotes begin
T694 59450-59452 TO denotes to
T695 59453-59460 VB denotes realize
T696 59461-59464 DT denotes the
T697 59465-59469 JJ denotes full
T698 59470-59479 NN denotes potential
T699 59480-59482 IN denotes of
T700 59483-59496 JJ denotes FcγR‐mediated
T701 59497-59505 NN denotes antibody
T702 59506-59512 JJ denotes immune
T703 59513-59525 NNS denotes therapeutics
T704 59526-59529 CC denotes and
T705 59530-59535 VB denotes offer
T706 59536-59552 JJ denotes transformational
T707 59553-59559 NN denotes change
T708 59560-59563 IN denotes for
T709 59564-59567 DT denotes the
T710 59568-59577 NN denotes treatment
T711 59578-59580 IN denotes of
T712 59581-59592 JJ denotes intractable
T713 59593-59596 CC denotes and
T714 59597-59606 JJ denotes incurable
T715 59607-59615 NNS denotes diseases
T716 59618-59626 NN denotes Conflict
T717 59627-59629 IN denotes of
T718 59630-59638 NN denotes Interest
T719 59639-59643 NN denotes None
R0 T1 T0 arg1Of expression,The
R1 T1 T2 arg1Of expression,of
R10 T12 T10 arg1Of or,the
R100 T94 T97 arg1Of enhancing,","
R101 T94 T98 arg1Of enhancing,as
R102 T99 T98 arg2Of described,as
R103 T99 T100 arg1Of described,previously
R104 T102 T101 arg1Of agonism,Immune
R105 T102 T103 arg1Of agonism,through
R106 T105 T103 arg2Of scaffolding,through
R107 T105 T104 arg1Of scaffolding,FcγR
R108 T107 T106 arg1Of mAbs,Agonistic
R109 T107 T108 arg1Of mAbs,induce
R11 T11 T12 arg1Of “sweeping”,or
R110 T109 T108 arg2Of responses,induce
R111 T109 T110 arg1Of responses,in
R112 T112 T110 arg2Of cells,in
R113 T112 T111 arg1Of cells,target
R114 T108 T113 arg1Of induce,by
R115 T114 T113 arg2Of stimulating,by
R116 T107 T114 arg1Of mAbs,stimulating
R117 T115 T114 arg2Of signaling,stimulating
R118 T115 T116 arg1Of signaling,of
R119 T119 T116 arg2Of target,of
R12 T13 T12 arg2Of removal,or
R120 T119 T117 arg1Of target,their
R121 T119 T118 arg1Of target,molecular
R122 T123 T120 arg1Of is,Typically
R123 T123 T121 arg1Of is,","
R124 T122 T123 arg1Of this,is
R125 T147 T123 arg2Of or,is
R126 T147 T124 arg1Of or,to
R127 T147 T125 arg1Of or,either
R128 T128 T126 arg2Of immunity,enhance
R129 T128 T127 arg1Of immunity,antitumor
R13 T12 T14 arg1Of or,of
R130 T126 T129 arg1Of enhance,by
R131 T130 T129 arg2Of engaging,by
R132 T132 T130 arg2Of molecules,engaging
R133 T132 T131 arg1Of molecules,costimulatory
R134 T132 T133 arg1Of molecules,on
R135 T136 T133 arg2Of or,on
R136 T135 T134 arg1Of cells,antigen‐presenting
R137 T135 T136 arg1Of cells,or
R138 T138 T136 arg2Of cells,or
R139 T138 T137 arg1Of cells,T
R14 T17 T14 arg2Of complexes,of
R140 T136 T139 arg1Of or,(
R141 T142 T139 arg2Of ",",(
R142 T146 T139 arg3Of ),(
R143 T142 T140 arg1Of ",",i.e.
R144 T141 T142 arg1Of CD40,","
R145 T143 T142 arg2Of 4‐1BB,","
R146 T142 T144 arg1Of ",",","
R147 T145 T144 arg2Of OX40,","
R148 T126 T147 arg1Of enhance,or
R149 T148 T147 arg2Of promote,or
R15 T17 T15 arg1Of complexes,small
R150 T149 T148 arg2Of apoptosis,promote
R151 T148 T150 arg1Of promote,by
R152 T151 T150 arg2Of engaging,by
R153 T153 T151 arg2Of receptors,engaging
R154 T153 T152 arg1Of receptors,death
R155 T153 T154 arg1Of receptors,on
R156 T156 T154 arg2Of cells,on
R157 T156 T155 arg1Of cells,cancer
R158 T156 T157 arg1Of cells,(
R159 T159 T157 arg2Of DR4,(
R16 T17 T16 arg1Of complexes,immune
R160 T164 T157 arg3Of ),(
R161 T159 T158 arg1Of DR4,i.e.
R162 T159 T160 arg1Of DR4,","
R163 T161 T160 arg2Of DR5,","
R164 T159 T162 arg1Of DR4,","
R165 T163 T162 arg2Of Fas,","
R166 T166 T165 arg1Of role,The
R167 T166 T167 arg1Of role,of
R168 T168 T167 arg2Of FcγR,of
R169 T166 T169 arg1Of role,in
R17 T6 T18 arg1Of and,has
R170 T171 T169 arg2Of action,in
R171 T171 T170 arg1Of action,the
R172 T171 T172 arg1Of action,of
R173 T174 T172 arg2Of types,of
R174 T174 T173 arg1Of types,these
R175 T174 T175 arg1Of types,of
R176 T176 T175 arg2Of mAbs,of
R177 T166 T177 arg1Of role,appears
R178 T179 T177 arg2Of be,appears
R179 T179 T178 arg1Of be,to
R18 T19 T18 arg2Of opened,has
R180 T166 T179 arg1Of role,be
R181 T181 T179 arg2Of as,be
R182 T181 T180 arg1Of as,primarily
R183 T166 T181 arg1Of role,as
R184 T183 T181 arg2Of scaffold,as
R185 T183 T182 arg1Of scaffold,a
R186 T184 T185 arg1Of FcγRIIb,is
R187 T189 T185 arg2Of receptor,is
R188 T185 T186 arg1Of is,often
R189 T189 T187 arg1Of receptor,the
R19 T6 T19 arg1Of and,opened
R190 T189 T188 arg1Of receptor,predominate
R191 T189 T190 arg2Of receptor,involved
R192 T185 T191 arg1Of is,and
R193 T197 T191 arg2Of is,and
R194 T193 T192 arg1Of extent,the
R195 T193 T194 arg1Of extent,of
R196 T196 T194 arg2Of involvement,of
R197 T196 T195 arg1Of involvement,its
R198 T193 T197 arg1Of extent,is
R199 T198 T197 arg2Of complex,is
R2 T3 T2 arg2Of FcγRIIb,of
R20 T22 T19 arg2Of possibilities,opened
R200 T193 T198 arg1Of extent,complex
R201 T212 T199 arg1Of linked,In
R202 T201 T199 arg2Of case,In
R203 T201 T200 arg1Of case,the
R204 T201 T202 arg1Of case,of
R205 T203 T202 arg2Of CD40,of
R206 T212 T204 arg1Of linked,","
R207 T206 T205 arg1Of degree,the
R208 T206 T207 arg1Of degree,of
R209 T210 T207 arg2Of potency,of
R21 T19 T20 arg1Of opened,up
R210 T210 T208 arg1Of potency,FcγRIIb
R211 T210 T209 arg1Of potency,scaffolding
R212 T206 T211 arg1Of degree,is
R213 T212 T211 arg2Of linked,is
R214 T232 T211 modOf is,is
R215 T206 T212 arg2Of degree,linked
R216 T212 T213 arg1Of linked,to
R217 T216 T213 arg2Of location,to
R218 T216 T214 arg1Of location,the
R219 T216 T215 arg1Of location,epitope
R22 T22 T21 arg1Of possibilities,new
R220 T216 T217 arg1Of location,of
R221 T219 T217 arg2Of targeting,of
R222 T219 T218 arg1Of targeting,the
R223 T218 T219 arg1Of the,targeting
R224 T220 T219 arg2Of mAb,targeting
R225 T219 T221 arg1Of targeting,with
R226 T223 T221 arg2Of potency,with
R227 T223 T222 arg1Of potency,greater
R228 T223 T224 arg2Of potency,seen
R229 T224 T225 arg1Of seen,for
R23 T22 T23 arg1Of possibilities,for
R230 T228 T225 arg2Of epitopes.43,for
R231 T228 T226 arg1Of epitopes.43,membrane
R232 T228 T227 arg1Of epitopes.43,proximal
R233 T216 T229 arg1Of location,","
R234 T230 T229 arg2Of 117,","
R235 T248 T231 arg1Of convert,It
R236 T248 T232 arg1Of convert,is
R237 T234 T232 arg2Of noteworthy,is
R238 T232 T233 arg1Of is,also
R239 T248 T234 arg1Of convert,noteworthy
R24 T25 T23 arg2Of application,for
R240 T248 T235 arg1Of convert,that
R241 T248 T236 arg1Of convert,depending
R242 T237 T236 arg2Of on,depending
R243 T240 T237 arg2Of location,on
R244 T240 T238 arg1Of location,the
R245 T240 T239 arg1Of location,epitope
R246 T248 T241 arg1Of convert,","
R247 T243 T242 arg1Of scaffolding,the
R248 T243 T244 arg1Of scaffolding,of
R249 T246 T244 arg2Of mAbs,of
R25 T25 T24 arg1Of application,the
R250 T246 T245 arg1Of mAbs,anti‐CD40
R251 T243 T247 arg1Of scaffolding,may
R252 T248 T247 arg2Of convert,may
R253 T243 T248 arg1Of scaffolding,convert
R254 T250 T248 arg2Of mAbs,convert
R255 T250 T249 arg1Of mAbs,antagonist
R256 T248 T251 arg1Of convert,to
R257 T252 T251 arg2Of agonistic,to
R258 T253 T254 arg1Of Engineering,of
R259 T258 T254 arg2Of region,of
R26 T25 T26 arg1Of application,of
R260 T258 T255 arg1Of region,the
R261 T258 T256 arg1Of region,IgG1
R262 T258 T257 arg1Of region,Fc
R263 T258 T259 arg1Of region,for
R264 T263 T259 arg2Of binding,for
R265 T263 T260 arg1Of binding,enhanced
R266 T260 T261 arg1Of enhanced,and/or
R267 T262 T261 arg2Of specific,and/or
R268 T263 T262 arg1Of binding,specific
R269 T263 T264 arg1Of binding,to
R27 T30 T26 arg2Of or,of
R270 T265 T264 arg2Of FcγRIIb,to
R271 T253 T266 arg1Of Engineering,can
R272 T268 T266 arg2Of improve,can
R273 T268 T267 arg1Of improve,greatly
R274 T253 T268 arg1Of Engineering,improve
R275 T270 T268 arg2Of function.72,improve
R276 T270 T269 arg1Of function.72,agonistic
R277 T270 T271 arg1Of function.72,","
R278 T272 T271 arg2Of 118,","
R279 T270 T273 arg1Of function.72,","
R28 T29 T27 arg1Of Antibodies,FcγRIIb‐enhancing
R280 T274 T273 arg2Of 119,","
R281 T268 T275 arg1Of improve,","
R282 T294 T275 arg2Of and,","
R283 T278 T276 arg1Of mutations,120
R284 T278 T277 arg1Of mutations,Such
R285 T278 T279 arg1Of mutations,induced
R286 T283 T279 arg2Of activity,induced
R287 T281 T280 arg1Of greater,significantly
R288 T283 T281 arg1Of activity,greater
R289 T283 T282 arg1Of activity,agonistic
R29 T29 T28 arg1Of Antibodies,modifications.17
R290 T279 T284 arg1Of induced,in
R291 T287 T284 arg2Of model,in
R292 T287 T285 arg1Of model,an
R293 T287 T286 arg1Of model,anti‐DR5
R294 T279 T288 arg1Of induced,through
R295 T290 T288 arg2Of induction,through
R296 T290 T289 arg2Of induction,increased
R297 T290 T291 arg1Of induction,of
R298 T293 T291 arg2Of death,of
R299 T293 T292 arg1Of death,apoptotic
R3 T1 T4 arg1Of expression,on
R30 T29 T30 arg1Of Antibodies,or
R300 T279 T294 arg1Of induced,and
R301 T295 T294 arg2Of decreased,and
R302 T278 T295 arg1Of mutations,decreased
R303 T297 T295 arg2Of growth,decreased
R304 T297 T296 arg1Of growth,tumor
R305 T295 T298 arg1Of decreased,compared
R306 T299 T298 arg2Of with,compared
R307 T301 T299 arg2Of IgG1.121,with
R308 T301 T300 arg1Of IgG1.121,unmodified
R309 T304 T302 arg1Of modifications,The
R31 T33 T30 arg2Of proteins,or
R310 T304 T303 arg1Of modifications,“SELF”
R311 T304 T305 arg1Of modifications,that
R312 T309 T306 arg1Of increase,dramatically
R313 T306 T307 arg1Of dramatically,and
R314 T308 T307 arg2Of selectively,and
R315 T309 T308 arg1Of increase,selectively
R316 T304 T309 arg1Of modifications,increase
R317 T310 T309 arg2Of affinity,increase
R318 T310 T311 arg1Of affinity,for
R319 T312 T311 arg2Of FcγRIIb,for
R32 T33 T31 arg1Of proteins,Fc
R320 T304 T313 arg1Of modifications,have
R321 T316 T313 arg2Of used,have
R322 T316 T314 arg1Of used,also
R323 T304 T315 arg1Of modifications,been
R324 T316 T315 arg2Of used,been
R325 T304 T316 arg2Of modifications,used
R326 T318 T316 arg3Of enhance,used
R327 T318 T317 arg1Of enhance,to
R328 T304 T318 arg1Of modifications,enhance
R329 T301 T318 arg2Of IgG1.121,enhance
R33 T33 T32 arg1Of proteins,fusion
R330 T320 T319 arg1Of agonism,immune
R331 T299 T320 arg1Of with,agonism
R332 T320 T321 arg1Of agonism,in
R333 T324 T321 arg2Of model.122,in
R334 T324 T322 arg1Of model.122,an
R335 T324 T323 arg1Of model.122,anti‐OX40
R336 T326 T325 arg1Of incorporation of,The
R337 T336 T326 arg1Of enhance,incorporation of
R338 T332 T327 arg1Of mutations,the
R339 T332 T328 arg1Of mutations,""""
R34 T22 T34 arg1Of possibilities,","
R340 T332 T329 arg1Of mutations,V12
R341 T332 T330 arg1Of mutations,""""
R342 T332 T331 arg1Of mutations,Fc
R343 T332 T333 arg1Of mutations,into
R344 T334 T333 arg2Of IgG1,into
R345 T336 T335 arg1Of enhance,specifically
R346 T332 T336 arg1Of mutations,enhance
R347 T338 T336 arg2Of interaction,enhance
R348 T338 T337 arg1Of interaction,FcγRIIb
R349 T336 T339 arg1Of enhance,200‐fold
R35 T37 T35 arg1Of MOA,whose
R350 T336 T340 arg1Of enhance,","
R351 T332 T341 arg1Of mutations,conferring
R352 T350 T341 arg2Of and,conferring
R353 T336 T341 modOf enhance,conferring
R354 T345 T342 arg1Of activity,the
R355 T345 T343 arg2Of activity,enhanced
R356 T345 T344 arg1Of activity,agonistic
R357 T345 T346 arg1Of activity,of
R358 T349 T346 arg2Of antibody,of
R359 T349 T347 arg1Of antibody,an
R36 T22 T35 arg2Of possibilities,whose
R360 T349 T348 arg1Of antibody,anti‐CD137
R361 T345 T350 arg1Of activity,and
R362 T353 T350 arg2Of mAb.115,and
R363 T353 T351 arg1Of mAb.115,an
R364 T353 T352 arg1Of mAb.115,anti‐OX40
R365 T353 T354 arg1Of mAb.115,","
R366 T355 T354 arg2Of 122,","
R367 T358 T356 arg1Of Strategies,Future
R368 T358 T357 arg1Of Strategies,Engineering
R369 T360 T359 arg1Of antibodies,Monoclonal
R37 T37 T36 arg1Of MOA,primary
R370 T360 T361 arg1Of antibodies,are
R371 T363 T361 arg2Of therapeutics,are
R372 T363 T362 arg1Of therapeutics,potent
R373 T361 T364 arg1Of are,in
R374 T366 T364 arg2Of number,in
R375 T366 T365 arg1Of number,a
R376 T366 T367 arg1Of number,of
R377 T372 T367 arg2Of diseases,of
R378 T372 T368 arg1Of diseases,chronic
R379 T368 T369 arg1Of chronic,or
R38 T37 T38 arg1Of MOA,is
R380 T371 T369 arg2Of incurable,or
R381 T371 T370 arg1Of incurable,once
R382 T372 T371 arg1Of diseases,incurable
R383 T376 T373 arg1Of is,However
R384 T376 T374 arg1Of is,","
R385 T375 T376 arg1Of there,is
R386 T384 T376 arg2Of as,is
R387 T376 T377 arg1Of is,still
R388 T380 T378 arg1Of clinical,extensive
R389 T380 T379 arg1Of clinical,unmet
R39 T40 T38 arg2Of neutralization,is
R390 T381 T380 arg1Of need,clinical
R391 T384 T382 arg1Of as,as
R392 T384 T383 arg1Of as,well
R393 T381 T384 arg1Of need,as
R394 T386 T384 arg2Of room,as
R395 T386 T385 arg1Of room,considerable
R396 T386 T387 arg1Of room,for
R397 T388 T387 arg2Of improvement,for
R398 T388 T389 arg1Of improvement,in
R399 T392 T389 arg2Of therapeutics,in
R4 T5 T4 arg2Of LSEC,on
R40 T40 T39 arg1Of neutralization,the
R400 T392 T390 arg1Of therapeutics,many
R401 T392 T391 arg1Of therapeutics,existing
R402 T394 T393 arg1Of understanding,Further
R403 T394 T395 arg1Of understanding,of
R404 T396 T395 arg2Of how,of
R405 T399 T396 arg1Of affects,how
R406 T398 T397 arg1Of structure,antibody
R407 T398 T399 arg1Of structure,affects
R408 T401 T399 arg2Of function,affects
R409 T401 T400 arg1Of function,FcγR
R41 T40 T41 arg1Of neutralization,of
R410 T394 T402 arg1Of understanding,is
R411 T403 T402 arg2Of essential,is
R412 T394 T403 arg1Of understanding,essential
R413 T403 T404 arg1Of essential,for
R414 T406 T404 arg2Of development,for
R415 T406 T405 arg1Of development,future
R416 T406 T407 arg1Of development,of
R417 T412 T407 arg2Of mAbs,of
R418 T412 T408 arg1Of mAbs,more
R419 T412 T409 arg1Of mAbs,potent
R42 T43 T41 arg2Of molecules,of
R420 T409 T410 arg1Of potent,and
R421 T411 T410 arg2Of effective,and
R422 T412 T411 arg1Of mAbs,effective
R423 T443 T413 arg1Of and,Already
R424 T443 T414 arg1Of and,","
R425 T415 T416 arg1Of engineering,of
R426 T420 T416 arg2Of and,of
R427 T419 T417 arg1Of Fc,the
R428 T419 T418 arg1Of Fc,IgG
R429 T419 T420 arg1Of Fc,and
R43 T43 T42 arg1Of molecules,soluble
R430 T422 T420 arg2Of glycan,and
R431 T422 T421 arg1Of glycan,its
R432 T415 T423 arg1Of engineering,has
R433 T424 T423 arg2Of proved,has
R434 T415 T424 arg1Of engineering,proved
R435 T435 T424 arg2Of ",",proved
R436 T429 T425 arg1Of approach,a
R437 T429 T426 arg1Of approach,potent
R438 T426 T427 arg1Of potent,and
R439 T428 T427 arg2Of effective,and
R44 T45 T44 arg1Of as,such
R440 T429 T428 arg1Of approach,effective
R441 T429 T430 arg1Of approach,for
R442 T431 T430 arg2Of increasing,for
R443 T434 T431 arg2Of effectiveness,increasing
R444 T434 T432 arg1Of effectiveness,the
R445 T434 T433 arg1Of effectiveness,clinical
R446 T429 T435 arg1Of approach,","
R447 T438 T435 arg2Of and,","
R448 T438 T436 arg1Of and,functional
R449 T437 T438 arg1Of specificity,and
R45 T43 T45 arg1Of molecules,as
R450 T439 T438 arg2Of safety,and
R451 T438 T440 arg1Of and,of
R452 T442 T440 arg2Of mAbs,of
R453 T442 T441 arg1Of mAbs,therapeutic
R454 T424 T443 arg1Of proved,and
R455 T444 T443 arg2Of is,and
R456 T415 T444 arg1Of engineering,is
R457 T447 T444 arg2Of pathway,is
R458 T447 T445 arg1Of pathway,an
R459 T447 T446 arg1Of pathway,emerging
R46 T47 T45 arg2Of or,as
R460 T447 T448 arg1Of pathway,to
R461 T450 T448 arg2Of development,to
R462 T450 T449 arg1Of development,the
R463 T450 T451 arg1Of development,of
R464 T454 T451 arg2Of therapeutics,of
R465 T454 T452 arg1Of therapeutics,the
R466 T454 T453 arg1Of therapeutics,“next‐gen”
R467 T456 T455 arg1Of directions,Future
R468 T456 T457 arg1Of directions,in
R469 T460 T457 arg2Of and,in
R47 T46 T47 arg1Of IgE,or
R470 T460 T458 arg1Of and,the
R471 T459 T460 arg1Of development,and
R472 T461 T460 arg2Of use,and
R473 T460 T462 arg1Of and,of
R474 T464 T462 arg2Of antibodies,of
R475 T464 T463 arg1Of antibodies,therapeutic
R476 T456 T465 arg1Of directions,should
R477 T467 T465 arg2Of mimic,should
R478 T467 T466 arg1Of mimic,increasingly
R479 T456 T467 arg1Of directions,mimic
R48 T48 T47 arg2Of cytokines,or
R480 T471 T467 arg2Of responses,mimic
R481 T471 T468 arg1Of responses,normal
R482 T471 T469 arg1Of responses,protective
R483 T471 T470 arg1Of responses,antibody
R484 T471 T472 arg1Of responses,","
R485 T471 T473 arg1Of responses,which
R486 T471 T474 arg1Of responses,are
R487 T476 T474 arg2Of and,are
R488 T471 T475 arg1Of responses,polyclonal
R489 T475 T476 arg1Of polyclonal,and
R49 T38 T49 arg1Of is,","
R490 T477 T476 arg2Of elicited,and
R491 T471 T477 arg2Of responses,elicited
R492 T477 T478 arg1Of elicited,in
R493 T480 T478 arg2Of context,in
R494 T480 T479 arg1Of context,the
R495 T480 T481 arg1Of context,of
R496 T484 T481 arg2Of engagement,of
R497 T484 T482 arg1Of engagement,innate
R498 T484 T483 arg1Of engagement,receptor
R499 T480 T485 arg1Of context,which
R5 T1 T6 arg1Of expression,and
R50 T50 T49 arg2Of are,","
R500 T480 T486 arg1Of context,includes
R501 T491 T486 arg2Of as,includes
R502 T491 T487 arg1Of as,the
R503 T491 T489 arg1Of as,as
R504 T491 T490 arg1Of as,well
R505 T488 T491 arg1Of FcR,as
R506 T495 T491 arg2Of systems,as
R507 T495 T492 arg1Of systems,other
R508 T495 T493 arg1Of systems,powerfully
R509 T495 T494 arg1Of systems,responsive
R51 T37 T50 arg1Of MOA,are
R510 T495 T496 arg1Of systems,including
R511 T500 T496 arg2Of and,including
R512 T500 T497 arg1Of and,the
R513 T499 T498 arg1Of receptors,Toll‐like
R514 T499 T500 arg1Of receptors,and
R515 T502 T500 arg2Of receptors,and
R516 T502 T501 arg1Of receptors,complement
R517 T514 T503 arg1Of suggests,Furthermore
R518 T514 T504 arg1Of suggests,","
R519 T508 T505 arg1Of nature,the
R52 T53 T50 arg2Of candidates,are
R520 T508 T506 arg1Of nature,mixed
R521 T508 T507 arg1Of nature,subclass
R522 T508 T509 arg1Of nature,of
R523 T513 T509 arg2Of responses,of
R524 T513 T510 arg1Of responses,these
R525 T513 T511 arg1Of responses,normal
R526 T513 T512 arg1Of responses,antibody
R527 T508 T514 arg1Of nature,suggests
R528 T518 T514 arg2Of arise,suggests
R529 T518 T515 arg1Of arise,that
R53 T52 T51 arg1Of attractive,particularly
R530 T516 T517 arg1Of circumstances,may
R531 T518 T517 arg2Of arise,may
R532 T516 T518 arg1Of circumstances,arise
R533 T518 T519 arg1Of arise,in
R534 T521 T519 arg2Of strategies,in
R535 T521 T520 arg1Of strategies,therapeutic
R536 T521 T522 arg1Of strategies,where
R537 T524 T522 arg2Of is,where
R538 T523 T524 arg1Of there,is
R539 T525 T524 arg2Of value,is
R54 T53 T52 arg1Of candidates,attractive
R540 T525 T526 arg1Of value,in
R541 T527 T526 arg2Of having,in
R542 T530 T527 arg2Of Fcs,having
R543 T530 T528 arg1Of Fcs,distinctly
R544 T530 T529 arg2Of Fcs,modified
R545 T530 T531 arg1Of Fcs,for
R546 T534 T531 arg2Of engagement,for
R547 T534 T532 arg1Of engagement,the
R548 T534 T533 arg1Of engagement,nuanced
R549 T534 T535 arg1Of engagement,of
R55 T53 T54 arg1Of candidates,for
R550 T539 T535 arg2Of members,of
R551 T539 T536 arg1Of members,different
R552 T539 T537 arg1Of members,FcγR
R553 T539 T538 arg1Of members,family
R554 T540 T541 arg1Of Treatments,comprising
R555 T544 T541 arg2Of and,comprising
R556 T543 T542 arg1Of mAbs,multiple
R557 T543 T544 arg1Of mAbs,and
R558 T546 T544 arg2Of stimulants,and
R559 T546 T545 arg1Of stimulants,immune
R56 T56 T54 arg2Of approach,for
R560 T540 T547 arg1Of Treatments,are
R561 T548 T547 arg2Of under,are
R562 T540 T548 arg1Of Treatments,under
R563 T549 T548 arg2Of investigation,under
R564 T547 T550 arg1Of are,in
R565 T552 T550 arg2Of disease,in
R566 T552 T551 arg1Of disease,infectious
R567 T552 T553 arg1Of disease,for
R568 T555 T553 arg2Of coverage,for
R569 T555 T554 arg1Of coverage,neutralization
R57 T56 T55 arg1Of approach,this
R570 T555 T556 arg1Of coverage,of
R571 T558 T556 arg2Of strains,of
R572 T558 T557 arg1Of strains,variant
R573 T565 T559 arg1Of be,Indeed
R574 T565 T560 arg1Of be,","
R575 T563 T561 arg1Of approach,such
R576 T563 T562 arg1Of approach,an
R577 T563 T564 arg1Of approach,may
R578 T565 T564 arg2Of be,may
R579 T563 T565 arg1Of approach,be
R58 T57 T58 arg1Of Proof‐of‐concept,for
R580 T567 T565 arg2Of effective,be
R581 T567 T566 arg1Of effective,most
R582 T563 T567 arg1Of approach,effective
R583 T567 T568 arg1Of effective,in
R584 T569 T568 arg2Of emerging,in
R585 T571 T569 arg2Of disease,emerging
R586 T571 T570 arg1Of disease,infectious
R587 T573 T572 arg1Of as,such
R588 T571 T573 arg1Of disease,as
R589 T583 T573 arg2Of infection,as
R59 T60 T58 arg2Of strategy,for
R590 T576 T574 arg1Of respiratory,severe
R591 T576 T575 arg1Of respiratory,acute
R592 T583 T576 arg1Of infection,respiratory
R593 T583 T577 arg1Of infection,syndrome
R594 T583 T578 arg1Of infection,coronavirus
R595 T583 T579 arg1Of infection,2
R596 T583 T580 arg1Of infection,(
R597 T581 T580 arg2Of SARS‐CoV‐2,(
R598 T582 T580 arg3Of ),(
R599 T585 T584 arg1Of use,The
R6 T8 T6 arg2Of action,and
R60 T60 T59 arg1Of strategy,this
R600 T585 T586 arg1Of use,of
R601 T588 T586 arg2Of mAbs,of
R602 T588 T587 arg1Of mAbs,multiple
R603 T588 T589 arg2Of mAbs,tailored
R604 T589 T590 arg1Of tailored,for
R605 T593 T590 arg2Of functions,for
R606 T593 T591 arg1Of functions,distinct
R607 T593 T592 arg1Of functions,effector
R608 T589 T594 arg1Of tailored,and
R609 T595 T594 arg2Of targeting,and
R61 T57 T61 arg1Of Proof‐of‐concept,has
R610 T588 T595 arg1Of mAbs,targeting
R611 T597 T595 arg2Of epitopes,targeting
R612 T597 T596 arg1Of epitopes,different
R613 T585 T598 arg1Of use,will
R614 T599 T598 arg2Of maximize,will
R615 T585 T599 arg1Of use,maximize
R616 T601 T599 arg2Of opportunity,maximize
R617 T601 T600 arg1Of opportunity,the
R618 T601 T602 arg1Of opportunity,for
R619 T603 T602 arg2Of cocktailing,for
R62 T63 T61 arg2Of demonstrated,has
R620 T603 T604 arg1Of cocktailing,of
R621 T606 T604 arg2Of functions,of
R622 T606 T605 arg1Of functions,effector
R623 T599 T607 arg1Of maximize,in
R624 T609 T607 arg2Of types,in
R625 T609 T608 arg1Of types,different
R626 T609 T610 arg1Of types,of
R627 T611 T610 arg2Of diseases,of
R628 T631 T612 arg1Of uses,Indeed
R629 T631 T613 arg1Of uses,","
R63 T57 T62 arg1Of Proof‐of‐concept,been
R630 T631 T614 arg1Of uses,in
R631 T619 T614 arg2Of example,in
R632 T619 T615 arg1Of example,a
R633 T619 T616 arg1Of example,small
R634 T616 T617 arg1Of small,but
R635 T618 T617 arg2Of contemporary,but
R636 T619 T618 arg1Of example,contemporary
R637 T619 T620 arg1Of example,outside
R638 T620 T621 arg1Of outside,of
R639 T623 T621 arg2Of disease,of
R64 T63 T62 arg2Of demonstrated,been
R640 T623 T622 arg1Of disease,infectious
R641 T631 T624 arg1Of uses,","
R642 T627 T625 arg1Of combination,the
R643 T627 T626 arg1Of combination,FDA‐approved
R644 T627 T628 arg1Of combination,in
R645 T630 T628 arg2Of therapy,in
R646 T630 T629 arg1Of therapy,adenocarcinoma
R647 T627 T631 arg1Of combination,uses
R648 T633 T631 arg2Of cocktail,uses
R649 T633 T632 arg1Of cocktail,a
R65 T57 T63 arg2Of Proof‐of‐concept,demonstrated
R650 T633 T634 arg1Of cocktail,of
R651 T636 T634 arg2Of mAbs,of
R652 T636 T635 arg1Of mAbs,two
R653 T633 T637 arg1Of cocktail,","
R654 T639 T637 arg2Of and,","
R655 T638 T639 arg1Of pertuzumab,and
R656 T640 T639 arg2Of trastuzumab,and
R657 T631 T641 arg1Of uses,","
R658 T631 T642 arg1Of uses,against
R659 T643 T642 arg2Of Her2.123,against
R66 T63 T64 arg1Of demonstrated,in
R660 T674 T644 arg1Of utilize,Rather
R661 T644 T645 arg1Of Rather,than
R662 T647 T645 arg2Of type,than
R663 T647 T646 arg1Of type,one
R664 T647 T648 arg1Of type,of
R665 T649 T648 arg2Of Fc,of
R666 T651 T650 arg1Of conquer,to
R667 T647 T650 modOf type,to
R668 T652 T651 arg2Of all,conquer
R669 T674 T653 arg1Of utilize,","
R67 T66 T64 arg2Of models.48,in
R670 T656 T654 arg1Of use,the
R671 T656 T655 arg1Of use,combined
R672 T656 T657 arg1Of use,of
R673 T660 T657 arg2Of mAbs,of
R674 T659 T658 arg1Of selected,appropriately
R675 T660 T659 arg1Of mAbs,selected
R676 T663 T661 arg1Of components,whose
R677 T660 T661 arg2Of mAbs,whose
R678 T663 T662 arg1Of components,individual
R679 T663 T664 arg1Of components,are
R68 T66 T65 arg1Of models.48,experimental
R680 T665 T664 arg2Of enhanced,are
R681 T663 T665 arg2Of components,enhanced
R682 T665 T666 arg1Of enhanced,for
R683 T668 T666 arg2Of engagement,for
R684 T668 T667 arg1Of engagement,the
R685 T668 T669 arg1Of engagement,of
R686 T672 T669 arg2Of members,of
R687 T672 T670 arg1Of members,different
R688 T672 T671 arg1Of members,FcγR
R689 T656 T673 arg1Of use,may
R69 T66 T67 arg1Of models.48,Indeed
R690 T674 T673 arg2Of utilize,may
R691 T656 T674 arg1Of use,utilize
R692 T676 T674 arg2Of components,utilize
R693 T676 T675 arg1Of components,multiple
R694 T676 T677 arg1Of components,of
R695 T679 T677 arg2Of spectrum,of
R696 T679 T678 arg1Of spectrum,the
R697 T679 T680 arg1Of spectrum,of
R698 T682 T680 arg2Of responses,of
R699 T682 T681 arg1Of responses,effector
R7 T8 T7 arg1Of action,its
R70 T63 T68 arg1Of demonstrated,","
R700 T679 T683 arg1Of spectrum,on
R701 T684 T683 arg2Of offer,on
R702 T674 T685 arg1Of utilize,by
R703 T688 T685 arg2Of system,by
R704 T688 T686 arg1Of system,the
R705 T688 T687 arg1Of system,immune
R706 T691 T689 arg1Of biologics,Such
R707 T691 T690 arg1Of biologics,“next‐gen”
R708 T691 T692 arg1Of biologics,will
R709 T693 T692 arg2Of begin,will
R71 T71 T68 arg2Of be,","
R710 T691 T693 arg1Of biologics,begin
R711 T704 T693 arg2Of and,begin
R712 T704 T694 arg1Of and,to
R713 T691 T695 arg1Of biologics,realize
R714 T698 T695 arg2Of potential,realize
R715 T698 T696 arg1Of potential,the
R716 T698 T697 arg1Of potential,full
R717 T698 T699 arg1Of potential,of
R718 T703 T699 arg2Of therapeutics,of
R719 T703 T700 arg1Of therapeutics,FcγR‐mediated
R72 T69 T70 arg1Of this,may
R720 T703 T701 arg1Of therapeutics,antibody
R721 T703 T702 arg1Of therapeutics,immune
R722 T695 T704 arg1Of realize,and
R723 T705 T704 arg2Of offer,and
R724 T691 T705 arg1Of biologics,offer
R725 T707 T705 arg2Of change,offer
R726 T707 T706 arg1Of change,transformational
R727 T705 T708 arg1Of offer,for
R728 T710 T708 arg2Of treatment,for
R729 T710 T709 arg1Of treatment,the
R73 T71 T70 arg2Of be,may
R730 T710 T711 arg1Of treatment,of
R731 T715 T711 arg2Of diseases,of
R732 T715 T712 arg1Of diseases,intractable
R733 T712 T713 arg1Of intractable,and
R734 T714 T713 arg2Of incurable,and
R735 T715 T714 arg1Of diseases,incurable
R736 T716 T717 arg1Of Conflict,of
R737 T718 T717 arg2Of Interest,of
R74 T69 T71 arg1Of this,be
R75 T74 T71 arg2Of component,be
R76 T74 T72 arg1Of component,a
R77 T74 T73 arg1Of component,significant
R78 T74 T75 arg1Of component,of
R79 T78 T75 arg2Of disappearance,of
R8 T8 T9 arg1Of action,in
R80 T78 T76 arg1Of disappearance,the
R81 T78 T77 arg1Of disappearance,rapid
R82 T78 T79 arg1Of disappearance,of
R83 T80 T79 arg2Of IgE,of
R84 T80 T81 arg1Of IgE,from
R85 T83 T81 arg2Of circulation,from
R86 T83 T82 arg1Of circulation,the
R87 T83 T84 arg1Of circulation,of
R88 T85 T84 arg2Of patients,of
R89 T85 T86 arg2Of patients,treated
R9 T12 T9 arg2Of or,in
R90 T86 T87 arg1Of treated,with
R91 T90 T87 arg2Of XmAb7195,with
R92 T90 T88 arg1Of XmAb7195,the
R93 T90 T89 arg1Of XmAb7195,anti‐IgE
R94 T90 T91 arg1Of XmAb7195,containing
R95 T93 T91 arg2Of FcγRIIb,containing
R96 T93 T92 arg1Of FcγRIIb,the
R97 T93 T94 arg1Of FcγRIIb,enhancing
R98 T96 T94 arg2Of modifications,enhancing
R99 T96 T95 arg1Of modifications,“SELF”